FDA dispute panel to review CardioGenesis' PMR (percutaneous myocardial revascularisation)
This article was originally published in Clinica
Executive Summary
The US FDA is to allow an independent panel to review a dispute over CardioGenesis' premarket approval (PMA) application for its controversial minimally invasive heart laser treatment for angina.